Drug Profile


Alternative Names: 1E10; 1E10 anti-idiotype vaccine therapy; Anti-idiotype antibody 1E10; Vaxira

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Center of Molecular Immunology
  • Developer Center of Molecular Immunology; Elea; Innogene Kalbiotech; Recombio
  • Class Antineoplastics; Cancer vaccines; Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase II Neuroblastoma
  • No development reported Breast cancer; Colorectal cancer; Malignant melanoma; Small cell lung cancer; Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(In children, In infants) in Argentina (Intradermal, Injection)
  • 01 Nov 2016 Phase-II clinical trials in Neuroblastoma (In children, In infants, Second-line therapy or greater) in Argentina (Intradermal) (NCT02998983)
  • 29 Aug 2016 The Center of Molecular Immunology plans a phase II/III trial for Non-small cell lung cancer (Adjuvant therapy) in Cuba (RPCEC00000207)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top